Product Description
A tamoxifen metabolite with both estrogenic and anti-estrogenic effects. Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/afimoxifene)
Mechanisms of Action: ER Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ascend
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Mastodynia|Breast Cancer|Soft Tissue Cancer|Ductal Breast Carcinoma|Intraductal Noninfiltrating Carcinoma|Ductal Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NU 18B05 | P2 |
Recruiting |
Intraductal Noninfiltrating Carcinoma|Breast Cancer|Ductal Carcinoma|Ductal Breast Carcinoma |
2024-01-31 |
2025-02-07 |
Primary Endpoints|Treatments |
|
| N01-CN-2012-00034 | P2 |
Completed |
Soft Tissue Cancer|Breast Cancer |
2021-10-26 |
2025-02-07 |
Primary Endpoints|Treatments |
|
| 4WARD Study | P3 |
Completed |
Unknown |
2020-11-16 |
2025-06-08 |
Treatments |
|
| NWU07-9-02 | P2 |
Completed |
Ductal Breast Carcinoma|Ductal Carcinoma|Intraductal Noninfiltrating Carcinoma|Breast Cancer |
2011-09-01 |
2025-02-07 |
Primary Endpoints|Treatments |
|
| NCI 00B3 | N/A |
Completed |
Breast Cancer |
2004-07-01 |
2019-03-21 |
Treatments |
|
| 01-4OHT-02 | P2 |
Completed |
Mastodynia |
2004-03-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/09/2024 |
PubMed |
Connexin 43 modulates reverse electron transfer in cardiac mitochondria from inducible knock-out Cx43Cre-ER(T)/fl mice by altering the coenzyme Q pool. |
|
04/20/2024 |
PubMed |
Conditional Depletion of STN1 in Mouse Embryonic Fibroblasts. |
|
03/27/2024 |
PubMed |
Patient-derived response estimates from zero-passage organoids of luminal breast cancer. |
|
05/20/2021 |
News Article |
Transdermal Drug Delivery Market Report 2020-2030 |
|
05/15/2020 |
News Article |
Worldwide Transdermal Drug Delivery Markets, Therapeutics, Technologies and Players - Forecast to 2028 |
|
05/15/2020 |
News Article |
Transdermal Drug Delivery Industry Assessment 2018-2028 Featuring Profiles of 100 Companies along with 105 Collaborations - ResearchAndMarkets.com |
|
08/01/2019 |
News Article |
Transdermal Drug Delivery Markets, 2028 |